SEC 13F Intelligence

Managers / Q4 2018 · view latest →

FRAZIER MANAGEMENT LLC

CIK 0001032165 · 601 UNION ST, SUITE 2110, SEATTLE, WA, 98101 · 2066217200

Reported Value
$388M
Q4 2018
Positions
17
Filings on Record
16
2019–present window
Filed
Feb 11, 2019
original filing

Summary

Frazier Management LLC reported $388M in U.S.-listed holdings across 17 positions for Q4 2018.

The portfolio is heavily concentrated: ANAB alone accounts for 38.1% of reported value.

Portfolio Metrics

Top-10 Concentration
+90.4%
share of reported value
Largest Position
+38.1%
Anaptysbio

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $388MQ4 ’18Q1 ’19: $415MQ2 ’19: $390MQ2 ’19Q3 ’19: $320MQ4 ’19: $596MQ4 ’19Q1 ’20: $882MQ2 ’20: $1.1BQ2 ’20Q3 ’20: $1.1BQ4 ’20: $1.3BQ4 ’20Q1 ’21: $1.2BQ2 ’21: $1.1BQ2 ’21Q3 ’21: $1.2BQ4 ’21: $1.3BQ4 ’21Q2 ’22: $1MQ3 ’22: $0Q3 ’22filingsflow.com

Portfolio Composition

By security type
Common Stock: 73.9%Other: 26.1%
  • Common Stock · 73.9% · $287M
  • Other · 26.1% · $101M

Quarter-over-Quarter Changes full breakdown →

IssuerMoveShare ΔShares nowValue ΔValue now
ANABANAPTYSBIO INCNEW+2.32M2.32M+$148M$148M
APTINYX INCNEW+3.19M3.19M+$53M$53M
COLLCOLLEGIUM PHARMACEUTICAL INCNEW+1.89M1.89M+$32M$32M
GRITSTONE ONCOLOGY INCNEW+2.06M2.06M+$32M$32M
IOVAIOVANCE BIOTHERAPEUTICS INCNEW+2.19M2.19M+$19M$19M
KRYSKRYSTAL BIOTECH INCNEW+875.0K875.0K+$18M$18M
ALLENA PHARMACEUTICALS INCNEW+3.33M3.33M+$18M$18M
MILLENDO THERAPEUTICS INCNEW+1.40M1.40M+$11M$11M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2018

17 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ANABANAPTYSBIO INChistory →COM38.13%$148M2.32M
2APTINYX INCCOM13.61%$53M3.19M
3COLLCOLLEGIUM PHARMACEUTICAL INChistory →COM8.36%$32M1.89M
4GRITSTONE ONCOLOGY INCCOM8.22%$32M2.06M
5IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM5.00%$19M2.19M
6KRYSKRYSTAL BIOTECH INChistory →COM4.69%$18M875.0K
7ALLENA PHARMACEUTICALS INCCOM4.68%$18M3.33M
8MILLENDO THERAPEUTICS INCCOM2.86%$11M1.40M
9SIERRA ONCOLOGY INCCOM2.76%$11M8.11M
10ALPINE IMMUNE SCIENCES INCCOM2.09%$8M2.20M
11ITERUM THERAPEUTICS PLCSHS1.99%$8M1.54M
12SYNLOGIC INCCOM1.57%$6M865.4K
13KEZAR LIFE SCIENCES INCCOM1.52%$6M250.0K
14NABRIVA THERAPEUTICS PLCSHS1.51%$6M4.01M
15ENTASIS THERAPEUTICS HLDGS ICOM1.42%$5M1.35M
16CIDARA THERAPEUTICS INCCOM0.80%$3M1.31M
17BELLICUM PHARMACEUTICALS INCCOM0.79%$3M1.05M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$01Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1M1Aug 10, 202213F-HRchanges · EDGAR ↗
Q1 2022Under review2May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$1.3B43Feb 8, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.2B41Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.1B34Aug 11, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.2B35May 12, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.3B35Feb 11, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.1B31Nov 12, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.1B26Aug 4, 202013F-HRchanges · EDGAR ↗
Q1 2020$882M25May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$596M20Feb 13, 202013F-HRchanges · EDGAR ↗
Q3 2019$320M19Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$390M18Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$415M17May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$388M17Feb 11, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.